Title:
HUMANIZED ANTIBODY CAPABLE OF BINDING TO HEG1 PROTEIN
Document Type and Number:
WIPO Patent Application WO/2023/277113
Kind Code:
A1
Abstract:
The present invention provides a humanized antibody capable of binding to HEG1 protein or an antigen-binding fragment thereof, the antibody being a humanized antibody capable of binding to human HEG1 protein expressed in a mesothelioma cell.
Inventors:
TSUJI SHOUTARO (JP)
IMAI KOHZOH (JP)
IMAI KOHZOH (JP)
Application Number:
PCT/JP2022/026140
Publication Date:
January 05, 2023
Filing Date:
June 30, 2022
Export Citation:
Assignee:
KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION (JP)
UNIV TOKYO (JP)
UNIV TOKYO (JP)
International Classes:
C07K16/28; A61K39/395; A61P35/00; C12N15/13
Domestic Patent References:
| WO2017141604A1 | 2017-08-24 |
Other References:
SHOUTARO TSUJI, KOTA WASHIMI, TAIHEI KAGEYAMA, MAKIKO YAMASHITA, MITSUYO YOSHIHARA, RIEKO MATSUURA, TOMOYUKI YOKOSE, YOICHI KAMEDA: "HEG1 is a novel mucin-like membrane protein that serves as a diagnostic and therapeutic target for malignant mesothelioma", SCIENTIFIC REPORTS, vol. 7, no. 1, 1 May 2017 (2017-05-01), XP055600682, DOI: 10.1038/srep45768
Attorney, Agent or Firm:
MORITA Yutaka (JP)
Download PDF:
Previous Patent: METHOD FOR PRODUCING MIXED TEMPURA
Next Patent: PHARMACEUTICAL COMPOSITION CONTAINING IRRADIATED HEMATOPOIETIC STEM CELLS
Next Patent: PHARMACEUTICAL COMPOSITION CONTAINING IRRADIATED HEMATOPOIETIC STEM CELLS